Month: May 2024

Record first quarter revenues of $2.8 billion, up 4.9% compared to first quarter 2023 Operating income of $154 million, up 9.2% compared to first quarter 2023 Net earnings of $153 million or $3.87 diluted earnings per share New contract awards of $3.1 billion, resulting in backlog of $48.4 billion Company reaffirms previously issued financial guidance1NEWPORT NEWS, Va., May 02, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) reported first quarter 2024 revenues of $2.8 billion, up 4.9% from the first quarter of 2023, driven primarily by growth at its Mission Technologies segment. Operating income in the first quarter of 2024 was $154 million and operating margin was 5.5%, compared to $141 million and 5.3%, respectively, in the first quarter of 2023. The increases were primarily driven by higher segment operating income2 compared to...

– Strong Growth and Leasing Activity – – Successful Execution on RPT Realty Acquisition – – Board Declares Quarterly Dividend – – Updates 2024 Outlook – JERICHO, N.Y., May 02, 2024 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the first quarter ended March 31, 2024. For the three months ended March 31, 2024 and 2023, Kimco Realty’s net (loss)/income available to the company’s common shareholders per diluted share was ($0.03) and $0.46, respectively. First Quarter HighlightsProduced Funds From Operations* (FFO) of $0.39 per diluted share. Generated 3.9% growth in Same Property Net Operating Income* (NOI) over the same period a...

– Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – – Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – – Presented preclinical data at the 2024 American Association for Cancer Research (AACR) Annual Meeting, demonstrating the potential therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy – AUSTIN, TX and DURHAM, NC., May 02, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage...

First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights:Revenue: Cloud subscription revenue was $86.6 million, up 24% compared to the first quarter of 2023. Total subscriptions revenue, which includes sales of our cloud subscriptions, on-premises term license subscriptions, and maintenance and support, increased 19% year-over-year to $117.7 million. Professional services revenue...

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into the first half of 2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the...

– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today reported business highlights...

Maintaining previously issued fiscal full year 2024 outlook Fiscal Second Quarter 2024 HighlightsRevenue decreased 7% to $488 million Same-store sales decreased 5% for the quarter; average annual increase of 4% over last two years Gross profit margin of 24.6% GAAP net loss of $(5) million, or $(0.27) per diluted share and adjusted diluted earnings per share1 of $0.67 Adjusted EBITDA1 was $28 millionBUFORD, Ga., May 02, 2024 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) today announced results for its fiscal second quarter ended March 31, 2024. “Our second quarter results were largely in line with our expectations and historical seasonality as we continue to outperform the industry. Like the first quarter, the selling environment remains competitive and boat pricing continues to moderate....

LOUDON, Tenn., May 02, 2024 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the third quarter ended March 31, 2024. Third Quarter Fiscal 2024 Highlights Compared to Third Quarter Fiscal 2023:Net sales decreased 45.8% to $203.4 million Unit volume decreased 51.9% to 1,269 units Gross profit decreased 59.1% to $40.3 million GAAP net income decreased 226.8% to a net loss of $67.8 million, inclusive of goodwill and other intangible asset impairment charges of $88.4 million incurred for the Maverick Boat Group reporting unit GAAP net income available to Class A Common Stock per share (diluted) decreased 230.7% to a net loss of $3.28 per share Adjusted EBITDA decreased 69.2% to $24.4 million Adjusted fully distributed net income per share decreased 75.7% to $0.63 per share on a fully...